Alidad Mireskandari

Abstract Buntanetap is an orally available small RNA targeting molecule that inhibits the translation of multiple neurotoxic aggregating proteins, including amyloid precursor protein (APP) and Tau. It has been evaluated in 13 clinical trials involving over 1000 participants, including healthy volunteers, patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD), and has shown a favorable safety and tolerability profile.

3. Results and Discussion 3.1. CogniMIR® 24-miRNA Panel We established a panel of 24 brain-enriched and inflammation-associated miRNAs detectable in plasma as a highly promising epigenetic biomarker of MCI and AD [1,4,11,18]. We initially selected miRNA biomarker candidates among those enriched in specific brain regions affected by the disease, such as the hippocampus in early MCI due to AD, present in synapses, and detectable in blood plasma.